Noninterventional studies of depot formulations of LHRH analogues for prostate cancer in routine clinical practice. The launch of an observational program to assess the use of Eligard 45 mg in Russia ; Неинтервенционные исследования депо-форм аналогов ЛГРГ при раке предстательной железы в рутинной клинической практике. Старт наблюдательной программы по оценке применения препарата Элигард 45 мг в России

Authors: V. B. Matveev, A. S. Markova, В. Б. Матвеев, А. С. Маркова

Source: Cancer Urology; Том 11, № 1 (2015); 68-72 ; Онкоурология; Том 11, № 1 (2015); 68-72 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2015-11-1

Subject Terms: депо-формы аналогов лютеинизирующего гормона рилизинг-го, observational studies, castration therapy, hormone therapy, prostate-specific antigen level, testosterone level, luteinizing hormone-releasing hormone, depot formulations of luteinizing hormone-releasing hormone, leuprorelin acetate, Elig, наблюдательные исследования, кастрационная терапия, гормональная терапия, уровень простатспецифического антигена, уровень тестостерона, лютеинизирующий гормон рилизинг-гормона

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/420/430; Вольская Е.А. Основы надлежащей практики неинтервенционных исследований лекарственных препаратов. Качественная клиническая практика 2011;1:19–24. [Volskaya E.A. The essentials of good clinical practice for non-interventional drug studies. Kachestvennaya klinicheskaya praktika = Good clinical practice 2011;1:19–24. (In Russ.)].; Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use.; Ouzaid I., Roupret M. The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: results from the ‘ELIRE’ observational study. Prog Urol 2011;21:866–74.; Montorsi F., Tomlinson P. Which luteinising hormone-releasing hormone agonist injection schedule do men with prostate cancer prefer? Results of a European patient survey. Eur Urol (2014). http://dx.doi.org/10.1016/j. eururo.2014.08.055Г; Perez-Marrero R., Chu F.M., Gleason D. et al. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 2002;24:1902–14.; Chu F.M., Jayson M., Dineen M.K. et al. A clinical study of 22.5 mg. LA-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002;168:1199–203.; Crawford E.D., Sartor O., Chu F. et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006;175:533–6.; Herdman M., Gudex C., Lloyd A. et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research 2011;20(10): 1727–36.; Tunn Ulf W. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. BMC Urology 2011. http://www.biomedcentral. com/1471-2490/11/15; Braeckman J., Michielsen D. Efficacy and tolerability of 1and 3-month leuprorelin acetate depot formulations (Eligard®/DepoEligard®) for advanced prostate cancer in daily practice: a Belgian prospective noninterventional study. Arch Med Sci 2014;10(3):477–483.; https://oncourology.abvpress.ru/oncur/article/view/420

Availability: https://oncourology.abvpress.ru/oncur/article/view/420
https://doi.org/10.17650/1726-9776-2015-1-68-72